Pharma BD Deal Intelligence
Outcome grade pending — assessed 5 years post-close.
Full analysis, sources & comparables →The acquisition adds a high-payload herpes simplex virus (HSV) gene therapy targeting genetic skin diseases to LEO Pharma's pipeline. HSV's natural tropism for…
LEO Pharma is making its first significant gene therapy bet through the $50 million acquisition of Replay, picking up a preclinical HSV-vectored topical gene…
Latham & Watkins, deal counsel to LEO Pharma, states LEO 'entered into a definitive agreement to acquire' Replay's gene therapy platform — confirming the…
Source summaries from our enrichment pipeline; follow links for originals.
All 8 sources with sentiment breakdown →
LEO Pharma signed a definitive agreement to acquire Replay for $50M upfront plus undisclosed milestones and tiered single-digit royalties, adding a preclinical HSV gene therapy platform targeting dystrophic epidermolysis bullosa to LEO's rare dermatology pipeline.
| Deal | Year | Value | Outcome |
|---|---|---|---|
| LEO Pharma A/S / Replay Holdings LLC (this deal) | 2026 | $50M | — |
| LEO Pharma A/S / AstraZeneca PLC | 2016 | $1.1B | 80 |
| Ciba-Geigy AG / Sandoz AG | 1996 | $36.3B | 98 |
| Sanofi SA / Regeneron Pharmaceuticals, Inc. | 2007 | $1.0B | 97 |
| AbbVie Inc. / Boehringer Ingelheim GmbH | 2016 | $2.2B | 95 |
| Amgen Inc. / Immunex Corporation | 2001 | $16.0B | 91 |
| Takeda Pharmaceutical Company Ltd. / Nimbus Lakshmi | 2022 | $6.0B | 82 |
← Browse all deals · How we score deals
More: 2026 deals · Dermatology deals